» Articles » PMID: 36275643

Targeted Nanoparticles Modify Neutrophil Function

Abstract

Neutrophils play critical roles in a broad spectrum of clinical conditions. Accordingly, manipulation of neutrophil function may provide a powerful immunotherapeutic approach. However, due to neutrophils characteristic short half-life and their large population number, this possibility was considered impractical. Here we describe the identification of peptides which specifically bind either murine or human neutrophils. Although the murine and human neutrophil-specific peptides are not cross-reactive, we identified CD177 as the neutrophil-expressed binding partner in both species. Decorating nanoparticles with a neutrophil-specific peptide confers neutrophil specificity and these neutrophil-specific nanoparticles accumulate in sites of inflammation. Significantly, we demonstrate that encapsulating neutrophil modifying small molecules within these nanoparticles yields specific modulation of neutrophil function (ROS production, degranulation, polarization), intracellular signaling and longevity both and . Collectively, our findings demonstrate that neutrophil specific targeting may serve as a novel mode of immunotherapy in disease.

Citing Articles

An insight into impact of nanomaterials toxicity on human health.

Qamar W, Gulia S, Athar M, Ahmad R, Imam M, Chandra P PeerJ. 2024; 12:e17807.

PMID: 39364370 PMC: 11448750. DOI: 10.7717/peerj.17807.


Advances in targeted delivery of mRNA into immune cells for enhanced cancer therapy.

Huang L, Huang Z, Zhang Y, Lin C, Zhao Z, Li R Theranostics. 2024; 14(14):5528-5550.

PMID: 39310113 PMC: 11413781. DOI: 10.7150/thno.93745.


Reflections on Targeting Neutrophil Extracellular Traps in Deep Vein Thrombosis.

Martinod K, Wagner D Arterioscler Thromb Vasc Biol. 2024; 44(8):1719-1724.

PMID: 39047082 PMC: 11279430. DOI: 10.1161/ATVBAHA.124.320148.


Nanoparticle-neutrophils interactions for autoimmune regulation.

Kupor D, Felder M, Kodikalla S, Chu X, Eniola-Adefeso O Adv Drug Deliv Rev. 2024; 209:115316.

PMID: 38663550 PMC: 11246615. DOI: 10.1016/j.addr.2024.115316.


Improving the Efficacy of Common Cancer Treatments via Targeted Therapeutics towards the Tumour and Its Microenvironment.

Cecchi D, Jackson N, Beckham W, Chithrani D Pharmaceutics. 2024; 16(2).

PMID: 38399237 PMC: 10891984. DOI: 10.3390/pharmaceutics16020175.


References
1.
Schreiber A, Eulenberg-Gustavus C, Bergmann A, Jerke U, Kettritz R . Lessons from a double-transgenic neutrophil approach to induce antiproteinase 3 antibody-mediated vasculitis in mice. J Leukoc Biol. 2016; 100(6):1443-1452. DOI: 10.1189/jlb.5A0116-037R. View

2.
Ley K, Hoffman H, Kubes P, Cassatella M, Zychlinsky A, Hedrick C . Neutrophils: New insights and open questions. Sci Immunol. 2018; 3(30). DOI: 10.1126/sciimmunol.aat4579. View

3.
Quail D, Amulic B, Aziz M, Barnes B, Eruslanov E, Fridlender Z . Neutrophil phenotypes and functions in cancer: A consensus statement. J Exp Med. 2022; 219(6). PMC: 9086501. DOI: 10.1084/jem.20220011. View

4.
Granot Z . Neutrophils as a Therapeutic Target in Cancer. Front Immunol. 2019; 10:1710. PMC: 6659000. DOI: 10.3389/fimmu.2019.01710. View

5.
Garley M, Jablonska E . Heterogeneity Among Neutrophils. Arch Immunol Ther Exp (Warsz). 2017; 66(1):21-30. PMC: 5767199. DOI: 10.1007/s00005-017-0476-4. View